TuHURA Biosciences (HURA) Common Equity (2010 - 2026)

TuHURA Biosciences' Common Equity history runs 17 years deep, the most recent figure standing at $23.2 million for Q1 2026.

• In Q1 2026, Common Equity rose 135.28% year-over-year to $23.2 million; the TTM figure through Mar 2026 stood at $23.2 million (up 135.28% YoY), while the FY2025 annual figure was $20.9 million, up 7415.29% from the prior year.
• Common Equity for Q1 2026 stood at $23.2 million, up from $20.9 million in the prior quarter.
• The five-year high for Common Equity was $23.2 million in Q1 2026, with the low at -$7.0 million in Q2 2024.
• The 5-year median for Common Equity is $9.4 million (2022), against an average of $7.0 million.
• The sharpest annual moves came in 2024 and 2025: Common Equity plunged 1051.96% in 2024, then soared 7415.29% in 2025.
• TuHURA Biosciences' Common Equity stood at $12.3 million in 2022, then sank by 112.67% to -$1.6 million in 2023, then surged by 117.87% to $278530.0 in 2024, then jumped by 7415.29% to $20.9 million in 2025, then climbed by 10.79% to $23.2 million in 2026.
• Business Quant data shows HURA's Common Equity at $23.2 million in Q1 2026, $20.9 million in Q4 2025, and $16.8 million in Q3 2025.